Valley National Advisers Inc. trimmed its position in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 97.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 378 shares of the company’s stock after selling 12,839 shares during the quarter. Valley National Advisers Inc.’s holdings in Astrazeneca were worth $61,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Amundi lifted its holdings in Astrazeneca by 146,574.4% during the first quarter. Amundi now owns 15,386,149 shares of the company’s stock worth $3,034,456,000 after acquiring an additional 15,375,659 shares in the last quarter. Janus Henderson Group PLC grew its stake in Astrazeneca by 889.9% in the first quarter. Janus Henderson Group PLC now owns 11,949,424 shares of the company’s stock valued at $2,319,947,000 after acquiring an additional 10,742,268 shares during the period. Rathbones Group PLC grew its stake in Astrazeneca by 106,772.0% in the first quarter. Rathbones Group PLC now owns 8,054,943 shares of the company’s stock valued at $1,560,419,000 after acquiring an additional 8,047,406 shares during the period. Royal Bank of Canada increased its holdings in shares of Astrazeneca by 208.6% in the first quarter. Royal Bank of Canada now owns 10,386,455 shares of the company’s stock worth $2,048,417,000 after acquiring an additional 7,021,126 shares in the last quarter. Finally, Swiss National Bank bought a new stake in shares of Astrazeneca in the first quarter worth about $1,202,714,000. Institutional investors and hedge funds own 20.35% of the company’s stock.
Astrazeneca Trading Up 0.3%
NYSE AZN opened at $172.03 on Tuesday. The stock has a market capitalization of $266.81 billion, a price-to-earnings ratio of 25.71, a PEG ratio of 1.33 and a beta of 0.27. The stock’s 50 day moving average price is $163.10 and its two-hundred day moving average price is $180.57. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.67 and a current ratio of 0.89. Astrazeneca Plc has a 52 week low of $153.41 and a 52 week high of $212.71.
Astrazeneca (NYSE:AZN – Get Free Report) last released its quarterly earnings results on Monday, July 27th. The company reported $2.63 earnings per share for the quarter, topping analysts’ consensus estimates of $2.50 by $0.13. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%. The firm had revenue of $15.38 billion during the quarter, compared to the consensus estimate of $15.44 billion. During the same quarter in the prior year, the firm posted $2.17 EPS. The business’s revenue was up 6.4% on a year-over-year basis. As a group, analysts anticipate that Astrazeneca Plc will post 10.23 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on the company. Weiss Ratings cut Astrazeneca from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, July 28th. Zacks Research raised Astrazeneca from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 13th. Deutsche Bank Aktiengesellschaft raised Astrazeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, September 15th. JPMorgan Chase & Co. restated a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 30th. Finally, Bank of America reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Wednesday, July 1st. Fifteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Astrazeneca has a consensus rating of “Moderate Buy” and an average target price of $206.67.
View Our Latest Stock Report on Astrazeneca
Astrazeneca Profile
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.
AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
See Also
- Five stocks we like better than Astrazeneca
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
